



## **Regeneron Announces September 2009 Investment Conference Presentations**

September 10, 2009

TARRYTOWN, N.Y., Sept 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations that are scheduled for delivery later this month at the following investment conferences:

- The Morgan Stanley Global Healthcare Unplugged Conference at 8:00 a.m. Eastern Time on Tuesday, September 15
- The NewsMakers in the Biotech Industry Conference at 9:00 a.m. Eastern Time on Wednesday, September 16
- The ThinkEquity Annual Growth Conference at 2:00 p.m. Eastern Time on Thursday, September 17
  
- The UBS Global Life Sciences Conference at 9:00 a.m. Eastern Time on Monday, September 21

The presentation at the Morgan Stanley Global Healthcare Unplugged Conference will be a conversation with Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, and a Morgan Stanley analyst. The presentations at the other conferences will provide an overview of the Company, including its three Phase 3 clinical programs.

The sessions may be accessed through the Company's web site, [www.regeneron.com](http://www.regeneron.com), on the Investor Relations page under the Presentations heading. Archived versions of the presentations will be available for thirty days after the live webcasts. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.

Contact Information:

Peter Dworkin	Laura Lindsay
Investor Relations	Media Relations
914.345.7640	914.345.7800
<a href="mailto:peter.dworkin@regeneron.com">peter.dworkin@regeneron.com</a>	<a href="mailto:laura.lindsay@regeneron.com">laura.lindsay@regeneron.com</a>

SOURCE Regeneron Pharmaceuticals, Inc.

<http://www.regeneron.com>

Copyright (C) 2009 PR Newswire. All rights reserved